Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet s… Read more
Xiangxue Pharmaceutical - Asset Resilience Ratio
Xiangxue Pharmaceutical (300147) has an Asset Resilience Ratio of 0.05% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Xiangxue Pharmaceutical's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Xiangxue Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥4.00 Million | 0.05% |
| Total Liquid Assets | CN¥4.00 Million | 0.05% |
Asset Resilience Insights
- Limited Liquidity: Xiangxue Pharmaceutical maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Xiangxue Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Xiangxue Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Xiangxue Pharmaceutical (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Xiangxue Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.17% | CN¥13.00 Million | CN¥7.50 Billion | +0.67pp |
| 2023-12-31 | -0.49% | CN¥-40.87 Million | CN¥8.28 Billion | -0.49pp |
| 2022-12-31 | 0.00% | CN¥125.98K | CN¥9.35 Billion | -0.58pp |
| 2021-12-31 | 0.58% | CN¥65.63 Million | CN¥11.38 Billion | +0.38pp |
| 2020-12-31 | 0.20% | CN¥19.34 Million | CN¥9.78 Billion | -0.14pp |
| 2019-12-31 | 0.34% | CN¥28.54 Million | CN¥8.46 Billion | +0.07pp |
| 2018-12-31 | 0.27% | CN¥23.34 Million | CN¥8.63 Billion | +0.44pp |
| 2017-12-31 | -0.17% | CN¥-16.17 Million | CN¥9.44 Billion | -0.50pp |
| 2016-12-31 | 0.33% | CN¥26.36 Million | CN¥7.99 Billion | -0.13pp |
| 2015-12-31 | 0.46% | CN¥21.27 Million | CN¥4.65 Billion | +0.64pp |
| 2014-12-31 | -0.18% | CN¥-6.46 Million | CN¥3.59 Billion | -0.19pp |
| 2010-12-31 | 0.01% | CN¥203.67K | CN¥1.85 Billion | -- |